

Triterpenes and Phenolic Compounds from *Euphorbia deightonii* with Antiviral Activity against Herpes Simplex Virus Type 2

SUPPLEMENTARY MATERIAL

Muhammad Bello Saidu,¹ Norbert Kúsz,¹ Yu-Chi Tsai,¹ Máté Vágvölgyi,¹ Róbert Berkecz,³ Dávid Kókai,³
Katalin Burián,³ Judit Hohmann,^{1,4} Dóra Rédei^{1*}

¹ Department of Pharmacognosy, University of Szeged, 6720 Szeged, Hungary;
bello.saidu@pharmacognosy.hu; kusznorbert@gmail.com; hohmann.judit@szte.hu;
redei@pharmacognosy.hu

² Albert Szent-Györgyi Medical School, Department of Medical Microbiology, University of Szeged, Dóm tér
10, 6720 Szeged, Hungary; kokai.david@med.u-szeged.hu; burian.katalin@med.u-szeged.hu

³ Institute of Pharmaceutical Analysis, University of Szeged, Somogyi u. 4, 6720 Szeged, Hungary;
berkecz.robert@szte.hu

⁴ Interdisciplinary Centre of Natural Products, University of Szeged, Eötvös u. 6, 6720 Szeged, Hungary;
hohmann.judit@szte.hu

TABLE OF CONTENT

Figure S1. ^1H NMR spectrum of compound 1 (500 MHz, in CDCl_3)	2
Figure S2. ^{13}C JMOD NMR spectrum of compound 1 (125 MHz, in CDCl_3)	2
Figure S3. HSQC spectrum of compound 1 (in CDCl_3)	3
Figure S4. ^1H – ^1H COSY spectrum of compound 1 (in CDCl_3)	3
Figure S5. HMBC spectrum of compound 1 (in CDCl_3)	4
Figure S6. NOESY spectrum of compound 1 (in CDCl_3)	4
Figure S7. ^1H NMR spectrum of compound 3 (500 MHz, in CDCl_3)	4
Figure S8. ^{13}C JMOD NMR spectrum of compound 3 (125 MHz, in CDCl_3)	4
Figure S9. ^1H NMR spectrum of compound 4 (500 MHz, in CDCl_3)	5
Figure S10. ^{13}C JMOD NMR spectrum of compound 4 (125 MHz, in CDCl_3)	5
Figure S11. HSQC spectrum of compound 4 (in CDCl_3)	6
Figure S12. ^1H – ^1H COSY spectrum of compound 4 (in CDCl_3)	6
Figure S13. HMBC spectrum of compound 4 (in CDCl_3)	7
Figure S14. NOESY spectrum of compound 4 (in CDCl_3)	7
Figure S15. HRMS spectrum of compound 1	8
Figure S16. HRMS spectrum of compound 4	8
Figure S17. Chiral chromatographic separation of compound 4	9
Figure S18. HPLC chromatogram of compound 1	9




Figure S1. ^1H NMR spectrum of compound **1** (500 MHz, in CDCl_3)




Figure S2. ^{13}C JMOD NMR spectrum of compound **1** (125 MHz, in CDCl_3)




Figure S3. HSQC spectrum of compound **1** (in CDCl₃)




Figure S4. ¹H–¹H COSY spectrum of compound **1** (in CDCl₃)




Figure S5. HMBC spectrum of compound **1** (in CDCl_3)




Figure S6. NOESY spectrum of compound **1** (in CDCl_3)




Figure S7. ^1H NMR spectrum of compound **3** (500 MHz, in CDCl_3)




Figure S8. ^{13}C JMOD spectrum of compound **3** (500 MHz, in CDCl_3)




Figure S9. ^1H NMR spectrum of compound **4** (500 MHz, in CDCl_3)




Figure S10. ^{13}C JMOD NMR spectrum of compound **4** (125 MHz, in CDCl_3)




Figure S11. HSQC spectrum of compound **4** (in CDCl_3)




Figure S12. ^1H - ^1H COSY spectrum of compound **4** (in CDCl_3)




Figure S13. HMBC spectrum of compound **4** (in CDCl₃)




Figure S14. NOESY spectrum of compound **4** (in CDCl₃)




Figure S15. HRMS spectrum of compound 1.




Figure S16. HRMS spektrum of compound 4.




Figure S17. Chiral chromatographic separation of compound **4**. Conditions: chromatographic instrument: Jasco HPLC/SFC instrument (Jasco International Co. Ltd., Hachioji, Tokyo, Japan) equipped with an MD-4015 PDA detector; stationary phase: Phenomenex Lux[®] 5 μm i-Amylose-1, 250 x 4.6 mm LC column (Phenomenex Inc., Torrance, CA, USA); mobile phase: 1 mL/min flow rate, isocratic elution, cyclohexane (+0.1% TFA) : tetrahydrofuran (+0.1% TFA) – 87 : 13.




Figure S18. HPLC chromatogram of compound **1**. Conditions: WUFENG HPLC instrument; column: LiChrospher Si 60 (5 μ m, 250-4 mm); mobile phase: *n*-Hexane–EtOAc (3:7); flow rate: 1.0 ml/min; RT 2.98 min